ClinicalTrials.gg
CompletedNCT07447141Updated Mar 3, 2026

DBM-1152A Inhalation Solution in Chinese Healthy Subjects

A Phase 1 interventional study of DBM-1152A Inhalation Solution and Placebo in Health and Health Adult Subjects, sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Dec 2023, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Enrollment
220th of 289
44 · median 160
Started
2023
with 44 others
Phase 1
29 of 407
5 open now
Registered
369th of 407
by date

Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 220th largest by enrollment of the 289 interventional ones that give a count, is one of 45 that started in 2023, is one of 29 in phase 1, and was the 369th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

This is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of DBM-1152A Inhalation Solution in healthy Chinese adult subjects.

03

Conditions studied

  • Health
  • Health Adult Subjects

Keywords

  • COPD
  • Asthma
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese healthy male or female subjects.
  2. Age 18 to 45 years (inclusive).
  3. Body weight: Male ≥50.0kg, Female≥45.0 kg; within the range of 19.0 to 26.0 kg/m\^2 (inclusive).
  4. Subjects (including their partners) are willing to use effective from the screening period until 6 months after the last dose.
  5. Subjects must fully understand the study, participate voluntarily, and sign the written .

Exclusion criteria

Exclusion Criteria:

  1. abnormalities in physical examination, chest X-ray, hematology, urinalysis, blood biochemistry, coagulation function, thyroid function, or ophthalmic examination during screening; or /FVC \< 80% in pulmonary function tests.
  2. Positive results in virology screening (, anti-, anti-, or TP-Ab).
  3. Abnormal vital signs at screening: Sitting systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, diastolic blood pressure \< 55 mmHg or ≥ 90 mmHg; Pulse \< 50 bpm or > 90 bpm; Body temperature \< 35.9°C or > 37.6°C; Respiratory rate \< 12 breaths/min or > 20 breaths/min.
  4. Clinically significant abnormalities in 12-lead , or interval (QTc): Male ≥ 450 ms, Female ≥ 470 ms.
  5. Electrolyte or glucose abnormalities at screening: Hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia, hypocalcemia, or hyperglycemia.
  6. Current acute or chronic oral or pharyngeal diseases (e.g., oral ulcers, pharyngitis).
  7. History or presence of chronic or severe diseases in the endocrine, urinary, digestive, hematological, respiratory, cardiovascular, neuropsychiatric, or immune systems, or any other physiological condition that may interfere with the study results.
  8. History or presence of glaucoma, functional constipation, prostatic hyperplasia, urinary tract obstruction, urinary retention, epilepsy, hyperthyroidism, paradoxical bronchospasm, diabetes, or ketoacidosis.
  9. History or presence of Short QT Syndrome or Long QT Syndrome.
  10. Lower respiratory tract infection within 6 weeks prior to screening, or clinically significant upper respiratory tract disease within 2 weeks prior to screening.
  11. Surgery within 3 months prior to screening, especially procedures affecting drug absorption, distribution, metabolism, or excretion; or planned surgery during the study.
  12. Suspected allergy to DBM-1152A or its ; history of to other anticholinergic drugs or β2-agonists; or history of significant food or drug allergies.
  13. History of drug abuse or drug dependence within 12 months prior to screening.
  14. Positive drug screening (morphine, methamphetamine, ketamine, MDMA, or THC) prior to enrollment.
  15. Excessive consumption of tea, coffee, or caffeinated beverages (≥8 cups/day, 250mL/cup) within the past 6 months; or consumption of caffeine-rich or grapefruit-rich food/beverages within 48 hours prior to screening.
  16. History of alcohol abuse within the past 12 months (Male ≥ 28 units/week, Female ≥ 21 units/week); or regular drinking (≥14 units/week) within 6 months prior to screening; or inability to abstain from alcohol during the study.
  17. Positive breath alcohol test (> 0 mg/100 mL) prior to enrollment.
  18. Current smoker or history of smoking.
  19. Positive nicotine test prior to enrollment.
  20. Use of any medications (including prescription, OTC, vitamins, herbal medicine, supplements, or vaccines) within 30 days prior to screening.
  21. Participation in any clinical trial of a drug or device within 3 months prior to screening.
  22. Blood donation or significant blood loss (> 400 mL) within 3 months prior to screening; or planned blood donation during or within 3 months after the study.
  23. Difficulty in venous blood collection or inability to tolerate venipuncture.
  24. History of needle syncope or blood syncope.
  25. Inability to tolerate inhalation administration.
  26. Strenuous exercise within 48 hours prior to screening.
  27. Pregnant or lactating women, or women planning pregnancy; use of long-acting estrogen/progestogen injections or implants within 6 months prior to screening; or positive pregnancy test.
  28. Male subjects (or their partners) or female subjects planning pregnancy, sperm donation, or egg donation within 6 months after the study, or unwilling to use .
  29. Special dietary requirements or inability to comply with the standardized diet.
  30. Poor compliance.
  31. Any other condition that, in the investigator's opinion, makes the subject unsuitable for enrollment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    1 mg DBM-1152A

    Participants receive a single dose of 1 mg DBM-1152A Inhalation Solution. (Sentinel cohort, open-label)

    Drug: DBM-1152A Inhalation Solution

  • Experimental
    2 mg DBM-1152A

    Participants receive a single dose of 2 mg DBM-1152A Inhalation Solution.

    Drug: DBM-1152A Inhalation Solution

  • Experimental
    4 mg DBM-1152A

    Participants receive a single dose of 4 mg DBM-1152A Inhalation Solution

    Drug: DBM-1152A Inhalation Solution

  • Experimental
    6 mg DBM-1152A

    Participants receive a single dose of 6 mg DBM-1152A Inhalation Solution.

    Drug: DBM-1152A Inhalation Solution

  • Experimental
    9 mg DBM-1152A

    Participants receive a single dose of 9 mg DBM-1152A Inhalation Solution.

    Drug: DBM-1152A Inhalation Solution

  • Placebo comparator
    Placebo

    Participants receive a single dose of matching placebo (blank vehicle) corresponding to the 2 mg, 4 mg, 6 mg, or 9 mg cohorts.

    Drug: Placebo

Interventions

  • DrugDBM-1152A Inhalation Solution

    Single dose via oral inhalation nebulization.

  • DrugPlacebo

    Single dose of blank vehicle via oral inhalation nebulization.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability

    Safety and tolerability are evaluated through adverse events (AEs), vital signs, physical examination, laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function), 12-lead ECG, Holter monitoring, and pupil examination.

    Time frame: From informed consent up to Day 4 (End of study).

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of DBM-1152A

    Maximum observed plasma concentration.

    Time frame: Pre-dose (within 1 hour before dosing) up to 72 hours post-dose.

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of DBM-1152A

    Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration.

    Time frame: Pre-dose (within 1 hour before dosing) up to 72 hours post-dose.

  3. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of DBM-1152A

    Area under the plasma concentration versus time curve from time 0 extrapolated to infinity.

    Time frame: Pre-dose (within 1 hour before dosing) up to 72 hours post-dose.

  4. Time to Reach Peak Plasma Concentration (Tmax) of DBM-1152A

    Time to reach maximum observed plasma concentration.

    Time frame: Pre-dose (within 1 hour before dosing) up to 72 hours post-dose.

  5. Apparent Terminal Elimination Half-Life (t1/2) of DBM-1152A

    Apparent terminal elimination half-life.

    Time frame: Pre-dose (within 1 hour before dosing) up to 72 hours post-dose.

  6. Apparent Total Plasma Clearance (CL/F) of DBM-1152A

    Apparent total plasma clearance calculated as dose divided by AUC0-∞.

    Time frame: Pre-dose (within 1 hour before dosing) up to 72 hours post-dose.

  7. Apparent Volume of Distribution (Vz/F) of DBM-1152A

    Apparent volume of distribution during the terminal phase.

    Time frame: Pre-dose (within 1 hour before dosing) up to 72 hours post-dose.

  8. Cumulative Amount of DBM-1152A Excreted Unchanged in Urine (Ae) (6 mg Cohort Only)

    Cumulative amount of unchanged drug excreted in the urine.

    Time frame: Pre-dose (within 24 hours before dosing) up to 72 hours post-dose.

07

Study locations

1 site
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared outside the sponsor organization. Data are not being made publicly available due to participant privacy and confidentiality considerations and because there is no established process for external data sharing for this study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Apr 2024, 3 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 3 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2026
First posted
Mar 3, 2026
StartActual
Dec 24, 2023
Primary completionActual
Apr 8, 2024
CompletionActual
Apr 8, 2024
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447141
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Dec 24, 2023
Primary completion
Apr 8, 2024
Completion
Apr 8, 2024
Last update
Mar 3, 2026

Study contacts

Yanmin Wu
principal investigator · Xuzhou Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion